 Shares of AMAG Pharmaceuticals NASDAQ:AMAG remained unaffected at 9.23 after the company reported Q1 results.Quarterly Results Earnings per share were up 20.00 over the past year to 0.72, which might not be comparable to the estimate of 0.03.Revenue of 68,661,000 lower by 9.42 year over year, which beat the estimate of 64,820,000.Guidance Earnings guidance hasnt been issued by the company for now.AMAG Pharmaceuticals hasnt issued any revenue guidance for the time being.Conference Call Details Date: May 11, 2020View more earnings on AMAGTime: 08:00 PM ETWebcast URL: Stock Performance Companys 52-week high was at 13.53Companys 52-week low was at 4.41Price action over last quarter: Up 19.25Company Profile AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.See more from Benzinga Recap: Recro Pharma Q1 Earnings Recap: GNC Holdings Q1 Earnings Pieris Pharmaceuticals: Q1 Earnings InsightsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 